

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Feb 2012

Therapeutic Registrations Only (Txca=Y)

9% of Calendar Year is Past

| Committee | Base Accrual 2009 | 2012 Percentage Accrual to date | Percentage of Base Accrual | Projected 2012 Accrual | Projected Increase <Decrease> from Base | Accrual Last 12 Months | 12 Month Increase <Decrease> from Base |
|-----------|----------------------|---------------------------------------|----------------------------------|------------------------------|--|------------------------------|---|
| BREAST | 4059 | 188 | 5% | 2018 | <2041> | 1446 | <2613> |
| ERLYTX | 41 | 0 | 0% | 0 | <41> | 4 | <37> |
| GI | 471 | 32 | 7% | 344 | <127> | 383 | <88> |
| GU | 810 | 69 | 9% | 741 | <69> | 439 | <371> |
| GYN | 0 | 0 | | 0 | 0 | 57 | 57 |
| LEUK | 323 | 25 | 8% | 268 | <55> | 178 | <145> |
| LUNG | 246 | 42 | 17% | 451 | 205 | 554 | 308 |
| LYMPH | 102 | 26 | 25% | 279 | 177 | 189 | 87 |
| MELAN | 111 | 13 | 12% | 140 | 29 | 73 | <38> |
| MMYEL | 123 | 24 | 20% | 258 | 135 | 236 | 113 |
| | 6286 | 419 | | 4498 | <1788> | 3559 | <2727> |

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Feb 2012

Non-Therapeutic Registrations Only

9% of Calendar Year is Past

| Committee | Base Accrual 2009 | 2012 Accrual to date | Percentage of Base Accrual | Projected 2012 Accrual | Projected | Accrual Last 12 Months | 12 Month |
|-----------|----------------------|----------------------------|----------------------------------|------------------------------|-------------------------------------|------------------------------|-------------------------------------|
| | | | | | Increase <Decrease> from Base | | Increase <Decrease> from Base |
| BREAST | 64 | 0 | 0% | 0 | <64> | 14 | <50> |
| GI | 0 | 0 | | 0 | 0 | 4 | 4 |
| GU | 0 | 2 | | 21 | 21 | 9 | 9 |
| LEUK | 328 | 0 | 0% | 0 | <328> | 53 | <275> |
| LUNG | 94 | 0 | 0% | 0 | <94> | 8 | <86> |
| LYMPH | 42 | 0 | 0% | 0 | <42> | 4 | <38> |
| MMYEL | 75 | 0 | 0% | 0 | <75> | 16 | <59> |
| PREV | 0 | 1 | | 11 | 11 | 4 | 4 |
| SXQOL | 33 | 0 | 0% | 0 | <33> | 0 | <33> |
| | 636 | 3 | | 32 | <604> | 112 | <524> |

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Feb 2012

All Initial Registrations

9% of Calendar Year is Past

| Committee | Base Accrual 2009 | 2012 Percentage Accrual to date | Percentage of Base Accrual | Projected 2012 Accrual | Projected Increase <Decrease> from Base | Accrual Last 12 Months | 12 Month Increase <Decrease> from Base |
|-----------|----------------------|---------------------------------------|----------------------------------|------------------------------|--|------------------------------|---|
| BREAST | 4123 | 188 | 5% | 2018 | <2105> | 1460 | <2663> |
| ERLYTX | 41 | 0 | 0% | 0 | <41> | 4 | <37> |
| GI | 471 | 32 | 7% | 344 | <127> | 387 | <84> |
| GU | 810 | 71 | 9% | 762 | <48> | 448 | <362> |
| GYN | 0 | 0 | | 0 | 0 | 57 | 57 |
| LEUK | 651 | 25 | 4% | 268 | <383> | 231 | <420> |
| LUNG | 340 | 42 | 12% | 451 | 111 | 562 | 222 |
| LYMPH | 144 | 26 | 18% | 279 | 135 | 193 | 49 |
| MELAN | 111 | 13 | 12% | 140 | 29 | 73 | <38> |
| MMYEL | 198 | 24 | 12% | 258 | 60 | 252 | 54 |
| PREV | 0 | 1 | | 11 | 11 | 4 | 4 |
| SXQOL | 33 | 0 | 0% | 0 | <33> | 0 | <33> |
| | 6922 | 422 | | 4530 | <2392> | 3671 | <3251> |

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Feb 2012

Therapeutic Registrations by SWOG Institutions Only (Txca=Y)

9% of Calendar Year is Past

| Committee | Base Accrual 2009 | 2012 Percentage Accrual to date | Percentage of Base Accrual | Projected 2012 Accrual | Projected Increase <Decrease> from Base | Accrual Last 12 Months | 12 Month Increase <Decrease> from Base |
|-----------|----------------------|---------------------------------------|----------------------------------|------------------------------|--|------------------------------|---|
| BREAST | 2292 | 116 | 5% | 1245 | <1047> | 959 | <1333> |
| ERLYTX | 41 | 0 | 0% | 0 | <41> | 4 | <37> |
| GI | 421 | 27 | 6% | 290 | <131> | 321 | <100> |
| GU | 599 | 60 | 10% | 644 | 45 | 396 | <203> |
| GYN | 0 | 0 | | 0 | 0 | 57 | 57 |
| LEUK | 192 | 23 | 12% | 247 | 55 | 155 | <37> |
| LUNG | 231 | 33 | 14% | 354 | 123 | 435 | 204 |
| LYMPH | 95 | 17 | 18% | 183 | 88 | 111 | 16 |
| MELAN | 97 | 13 | 13% | 140 | 43 | 73 | <24> |
| MMYEL | 64 | 16 | 25% | 172 | 108 | 144 | 80 |
| | 4032 | 305 | | 3274 | <758> | 2655 | <1377> |

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Feb 2012

Non-Therapeutic Registrations by SWOG Institutions Only

9% of Calendar Year is Past

| Committee | Base Accrual 2009 | 2012 Accrual to date | Percentage of Base Accrual | Projected 2012 Accrual | Projected Increase <Decrease> from Base | Accrual Last 12 Months | 12 Month Increase <Decrease> from Base |
|-----------|----------------------|----------------------------|----------------------------------|------------------------------|--|------------------------------|---|
| BREAST | 10 | 0 | 0% | 0 | <10> | 1 | <9> |
| GI | 0 | 0 | | 0 | 0 | 4 | 4 |
| GU | 0 | 2 | | 21 | 21 | 9 | 9 |
| LEUK | 318 | 0 | 0% | 0 | <318> | 53 | <265> |
| LUNG | 78 | 0 | 0% | 0 | <78> | 7 | <71> |
| LYMPH | 42 | 0 | 0% | 0 | <42> | 4 | <38> |
| MMYEL | 75 | 0 | 0% | 0 | <75> | 16 | <59> |
| PREV | 0 | 1 | | 11 | 11 | 4 | 4 |
| SXQOL | 33 | 0 | 0% | 0 | <33> | 0 | <33> |
| | 556 | 3 | | 32 | <524> | 98 | <458> |

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Feb 2012

All Initial Registrations by SWOG Institutions

9% of Calendar Year is Past

| Committee | Base Accrual 2009 | 2012 Percentage Accrual to date | Percentage of Base Accrual | Projected 2012 Accrual | Projected Increase <Decrease> from Base | Accrual Last 12 Months | 12 Month Increase <Decrease> from Base |
|-----------|----------------------|---------------------------------------|----------------------------------|------------------------------|--|------------------------------|---|
| BREAST | 2302 | 116 | 5% | 1245 | <1057> | 960 | <1342> |
| ERLYTX | 41 | 0 | 0% | 0 | <41> | 4 | <37> |
| GI | 421 | 27 | 6% | 290 | <131> | 325 | <96> |
| GU | 599 | 62 | 10% | 666 | 67 | 405 | <194> |
| GYN | 0 | 0 | | 0 | 0 | 57 | 57 |
| LEUK | 510 | 23 | 5% | 247 | <263> | 208 | <302> |
| LUNG | 309 | 33 | 11% | 354 | 45 | 442 | 133 |
| LYMPH | 137 | 17 | 12% | 183 | 46 | 115 | <22> |
| MELAN | 97 | 13 | 13% | 140 | 43 | 73 | <24> |
| MMYEL | 139 | 16 | 12% | 172 | 33 | 160 | 21 |
| PREV | 0 | 1 | | 11 | 11 | 4 | 4 |
| SXQOL | 33 | 0 | 0% | 0 | <33> | 0 | <33> |
| | 4588 | 308 | | 3306 | <1282> | 2753 | <1835> |

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Feb 2012

Initial Registrations to Cancer Control Studies

9% of Calendar Year is Past

| Committee | Base Accrual 2009 | 2009 Accrual to date | Percentage of Base Accrual | Projected 2009 Accrual | Projected | Accrual | 12 Month |
|-----------|----------------------|-------------------------|----------------------------------|------------------------------|-------------------------|-------------------|-------------------------|
| | | | | | <Decrease> from Base | Last 12 Months | <Decrease> from Base |
| BREAST | 188 | 95 | 51% | 1020 | 832 | 516 | 328 |
| GI | 0 | 1 | | 11 | 11 | 4 | 4 |
| GU | 496 | 0 | 0% | 0 | <496> | 0 | <496> |
| LUNG | 88 | 0 | 0% | 0 | <88> | 14 | <74> |
| LYMPH | 4 | 0 | 0% | 0 | <4> | 0 | <4> |
| PREV | 0 | 1 | | 11 | 11 | 4 | 4 |
| SXQOL | 33 | 0 | 0% | 0 | <33> | 0 | <33> |
| | 809 | 97 | | 1041 | 232 | 538 | <271> |

| Comm. | Phase | Study | Stat Center | Open Date | Months Open | Total Regs | Accrual Goal | Monthly Date of | |
|---------------------------------------|-------|---|-------------|-----------|-------------|------------|--------------|-----------------|---------------------------------------|
| | | | | | | | | Accrual Rate | Expected Closure or Temporary Closure |
| BREAST | II | Z1071 Node+, chemo + LN dissect | ACOSOG | 22-JUL-09 | | 67 | | .0 | |
| | | S0800 Brst,Neoadj nabPAC+/-Bev->AC+G | SWOG | 01-APR-10 | 22 | 123 | 200 | 9.0 | Oct-2012 |
| | | C40603 Carb/Bev+Neoadj Pac, then AC/EC | CALGB | 21-MAY-10 | | 35 | | 1.5 | |
| | | E3108 CYP2D6 Activity&SingleAgTamox | ECOG | 08-OCT-10 | | 5 | | .8 | |
| | III | C40101 Breast, Adj, Node neg, AC vs T | CALGB | 15-MAY-02 | | 733 | | .0 | |
| | | JMA20 Breast, Early, Regional RT | NCIC | 03-OCT-02 | | 8 | | .0 | |
| | | IBC24-02 Ovar Ftn suppress/premeno | IBCSG | 04-AUG-03 | | 187 | | .0 | |
| | | B39 Stg 0-2, whole vs partial RT | NSABP | 22-MAR-05 | | 14 | | .0 | |
| | | C70301 QOLEmployInformCareCost Analysis | CALGB | 24-OCT-05 | | 35 | | .0 | |
| | | N0434 JMA27 Companion Study | NCCTG | 08-DEC-05 | | 100 | | .0 | |
| | | JMA27B 5yr Adj Anast vs Exemestrane | NCIC | 24-APR-06 | | 94 | | .0 | |
| | | PACCT-1 Assess of Ca Clinical Tests | ECOG | 24-APR-06 | | 1712 | | .0 | |
| | | C40302 Endocrine +/- Inhibition | CALGB | 22-SEP-06 | | 28 | | .0 | |
| | | S0500 Brst,Adv,CTC,mntain v chnge tx | SWOG | 01-OCT-06 | 64 | 604 | 500 | 10.7 | May-2011 |
| | | E1105 Adv, Trastuzumab +/- Bev | ECOG | 21-NOV-07 | | 15 | | .0 | |
| | | N063D ALTTO | NCCTG | 15-FEB-08 | | 119 | | .0 | |
| | | C40503 EndocrineTxCombo w/AntiVEGF Tx | CALGB | 22-MAY-08 | | 39 | | .7 | |
| | | N0733 Her2+, Cap + Lap +/- IMC-A12 | NCCTG | 30-JUL-08 | | 5 | | .3 | |
| | | C40601 NeoAdj, Her-2+, Pac+Trast or Lap | CALGB | 08-DEC-08 | | 30 | | 2.3 | |
| | | MA32 Metformn vs Placebo | NCIC | 08-JUL-10 | | 250 | | 37.2 | |
| B47 Chemo vs Chemo + Trastuzumab | NSABP | 07-JAN-11 | | 15 | | 1.5 | | | |
| S1007 Breast,Adj,N1,Endocrine+/-Chemo | SWOG | 15-JAN-11 | 12 | 252 | 4000 | 35.5 | Nov-2020 | | |
| E2108 Early Local Tx for Int Prim Tum | ECOG | 28-FEB-11 | | 3 | | .3 | | | |
| ERLYTX | I | S0711 Liver dysfunction PK,Dasatinib | SWOG | 15-OCT-08 | | 54 | 48 | | Jan-2012 Temp Close |
| GI | II | S0809 EHCC,Adj,Cape+Gem==>Cape+RT | SWOG | 01-DEC-08 | 38 | 99 | 88 | 3.8 | Dec-2011 |
| | | S0713 Rect,Stg2-3,Ox/Cape/Cet+RT->SRG | SWOG | 01-FEB-09 | 36 | 55 | 88 | 2.0 | Jun-2013 |
| | | S1005 Gastric/GEJ, Adv, MK-2206 | SWOG | 01-JAN-11 | 13 | 25 | 64 | 2.7 | Apr-2013 |
| | III | C80405 GI,Met,FOLFOX/FIRI,Bev,Cetux | CALGB | 26-SEP-05 | | 640 | 2289 | 5.7 | |
| | | S0518 CARCINOID,ADV,OCTREO/ALPHA/BEV | SWOG | 01-DEC-07 | 50 | 375 | 424 | 7.0 | Aug-2012 |
| | | E1208 Chemo Soraf. in Unresect HCC | ECOG | 09-NOV-09 | | 16 | | 1.8 | |
| | | R0848 Panc, Adj, Erlotinib v ChemoRT | RTOG | 08-DEC-09 | | 6 | | .5 | |
| | | C80802 Soraf+Doxorubicin vs Sorafenib | CALGB | 22-FEB-10 | | 3 | | .3 | |
| | | C80702 Adj FOLFOX+Celecoxib or Placebo | CALGB | 22-JUN-10 | | 113 | | 7.7 | |
| R1010 Trastuz + Tri Tx of HER2-Overex | RTOG | 07-JAN-11 | | 1 | | .2 | | | |

| Comm. | Phase | Study | Stat Center | Open Date | Months Open | Total Regs | Accrual Goal | Monthly Date of | |
|-------|-------|---|---------------------------------------|-----------|-------------|------------|--------------|-----------------|---------------------------------------|
| | | | | | | | | Accrual Rate | Expected Closure or Temporary Closure |
| GU | II | S0925 Andro Dep w/IMC vs. Andro Dep | SWOG | 15-DEC-10 | 13 | 89 | 198 | 9.7 | Jan-2013 |
| | | S1014 Pros, Mets, Abi Acetate | SWOG | 09-AUG-11 | 5 | 0 | 38 | .0 | > 15 Yrs |
| | III | MDA3410 Consolidation chemo | MDACC | 08-MAY-02 | | 22 | | .0 | |
| | | C90202 Pros,Bone mets,Zoledronic acid | CALGB | 15-JAN-04 | | 77 | | .5 | |
| | | R0521 AS+RT vs AS+RT+Chemo | RTOG | 22-DEC-05 | | 18 | | .0 | |
| | | R0415 Hypofrac v Conv 3D-CRG/IMRT | RTOG | 24-APR-06 | | 1 | | .0 | |
| | | E2805 Renal, Adj Sunitib v Sorafinib | ECOG | 08-MAY-06 | | 583 | | .0 | |
| | | E3805 CHAARTED | ECOG | 08-AUG-06 | | 125 | | 3.0 | |
| | | R0524 Pac + Trastuzumab vs Pac alone | RTOG | 08-DEC-06 | | 5 | | .0 | |
| | | C90203 Pros, Surgery +/- Neoadj Chemo | CALGB | 22-DEC-06 | | 83 | | 1.2 | |
| | | S0337 Blad, Instill Gem vs Saline | SWOG | 15-JUL-07 | 54 | 312 | 408 | 14.2 | Aug-2012 |
| | | PR11 Pros, Local, Watch vs Active Tx | NCIC | 15-JUL-07 | | 8 | | .0 | |
| | | E2804 BeST Trial | ECOG | 21-MAR-08 | | 44 | | .0 | |
| | | C90601 Trans cell, blind bev vs placebo | CALGB | 07-AUG-09 | | 39 | | 2.0 | |
| | | C70807 MEAL Study | CALGB | 21-JAN-11 | | 9 | | 1.5 | |
| | | S0931 EVEREST | SWOG | 01-APR-11 | 10 | 104 | 1218 | 16.2 | Oct-2017 |
| | | S1011 Blad, Standard vs Extended LND | SWOG | 01-AUG-11 | 6 | 11 | 620 | 1.8 | > 15 Yrs |
| LEUK | II | S0535 APL,High Risk, ATRA/arsenic/GO | SWOG | 15-NOV-07 | 50 | 54 | 77 | 2.0 | Jan-2013 |
| | | C10403 ALL <40 yrs-Ped,Chemo. Regimen | CALGB | 15-JAN-08 | 48 | 65 | 300 | 2.2 | |
| | | S0703 AML, age 60+, Azacitidine G.O. | SWOG | 01-DEC-08 | 38 | 132 | 153 | 4.3 | Jun-2012 |
| | | C10404 CLL, Flu/Rituxan combinations | CALGB | 15-MAR-09 | 34 | 26 | 300 | 1.0 | |
| | | S0919 Rel AML: Pravastatin+Ida+Ara-C | SWOG | 15-AUG-09 | 29 | 25 | 55 | 1.3 | Dec-2013 |
| | | S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT | SWOG | 01-SEP-09 | 29 | 23 | 94 | 2.0 | Jan-2015 |
| | | S0910 Rel ph-,B-ALL,Epratuzumab+Cy+Clo | SWOG | 15-AUG-10 | 17 | 25 | 35 | 2.2 | Jun-2012 |
| | | E1908 Tx of PCL Leuk w/Alemtuz, Ritux | ECOG | 22-OCT-10 | | 1 | | .2 | |
| | III | E2905 MDS, Len vs Len + Epo | ECOG | 09-FEB-09 | | 21 | | .7 | |
| | LUNG | I-II | S0905 Mesothem,cediranib+chemo,PhI/II | SWOG | 15-MAR-10 | 22 | 25 | 128 | .8 |
| II | | S0720 NSCLC,STG I,ERCC1/RRM1 TO ADJ TX | SWOG | 15-NOV-08 | | 85 | 60 | | Apr-2011 Temp Close |
| | | S0709 NSCLC, Adv, PRO+, OSI-774+-Chemo | SWOG | 01-DEC-08 | 38 | 37 | 110 | 1.5 | Feb-2016 |
| | | S0802 ESCLC,Topotecan+/-AVE0005,PhII | SWOG | 15-MAY-09 | 32 | 188 | 190 | 4.5 | Feb-2012 |
| III | | E1505 Stg IB-III A chemo +/- Bev | ECOG | 22-JUN-07 | | 216 | | 4.0 | |

| Comm. | Phase | Study | Stat Center | Open Date | Months Open | Total Regs | Accrual Goal | Monthly Date of | |
|-------|-------|--|--|-----------|-------------|------------|--------------|-----------------|---------------------------------------|
| | | | | | | | | Accrual Rate | Expected Closure or Temporary Closure |
| LUNG | III | C140503 NSCL, Lobect v Sublobar resect | CALGB | 09-JUL-07 | | 13 | | .2 | |
| | | C30610 SCLC, Thoracic RT | CALGB | 21-MAR-08 | | 29 | | .7 | |
| | | S0819 NSCLC, ADV, CHEMO/BEV +/-CET | SWOG | 15-JUL-09 | 30 | 643 | 1700 | 26.7 | May-2015 |
| | | C30801 Selective COX-2 Inhibition | CALGB | 22-JUL-10 | | 5 | | .2 | |
| | | N107C SRS vs WBRT on Resected Met Dz | NCCTG | 08-JUL-11 | | 0 | | .0 | |
| LYMPH | I-II | S0806 NHL, Adv, R-CHOP + SAHA | SWOG | 15-NOV-10 | 14 | 25 | 105 | 2.8 | Jun-2014 |
| | | II | S0816 HD, Adv, PET-Adapted Therapy | SWOG | 01-JUL-09 | 31 | 235 | 200 | 11.8 |
| | | C50604 Resp-Adapt Chemo Pos Emiss Tomo | CALGB | 22-JUL-10 | | 15 | | 1.3 | |
| | | S1001 DLBCL, I-II, PET-Adapted Therapy | SWOG | 15-JUL-11 | 6 | 3 | 155 | .5 | > 15 Yrs |
| | | S1106 NHL, Adv, R-HCVAD/R-Benda+PBSCT | SWOG | 01-OCT-11 | 4 | 3 | 180 | .7 | > 15 Yrs |
| | | S1108 NHL, Relapsed PTCL, MLN8237 | SWOG | 28-OCT-11 | 3 | 2 | 39 | .6 | Jan-2017 |
| | III | C50303 R-CHOP v EPOCH-R | CALGB | 15-SEP-06 | | 43 | | .7 | |
| | | CTN0701 Relapsed follic, allo transplant | BMT-CT | 23-FEB-09 | | 3 | | .0 | |
| | | | N | | | | | | |
| | MELAN | II | E2607 Dasatinib in KIT+ pts w/Melanoma | ECOG | 22-NOV-11 | | 0 | | |
| III | | E1609 Adj Ipil AntiCTLA4 vs Interferon | ECOG | 08-JUN-11 | | 41 | | 6.8 | |
| MMYEL | II | S0833 Frontline MM, Total Therapy III | SWOG | 15-MAR-11 | 10 | 0 | 100 | .0 | > 15 Yrs |
| | III | S0777 MM, Len Dex +/- Bortezomib | SWOG | 01-APR-08 | 46 | 525 | 484 | 15.7 | Dec-2011 |
| | | CTN0702 Single v Tandem Autol transplant | BMT-CT | 09-JUN-10 | | 12 | | .8 | |
| | | E3A06 Lenalidomide vs Observation | ECOG | 08-NOV-10 | | 7 | | .3 | |
| | | E4A08 MDex vs BMDex in untx pts w/AL | ECOG | 22-NOV-10 | | 0 | | .0 | |
| PREV | II | S0812 Breast, Prev, Vit D vs Placebo | SWOG | 01-NOV-11 | 3 | 4 | 220 | 1.3 | Dec-2025 |

| Comm. | Phase | Study | Stat Center | Open Date | Months Open | Total Regs | Accrual Goal | Monthly Date of | |
|-------|-------|--|----------------|--------------|----------------|---------------|-----------------|-----------------|--|
| | | | | | | | | Accrual Rate | Expected Closure or Temporary Closure |
| SXQOL | III | S0927 Omega-3-Fatty Acid AI Joint Pain | SWOG | 01-FEB-12 | 0 | 0 | 246 | | |

Accrual goals assume studies are not terminated early as a result of interim analysis.
 Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
 Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
 Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center

[comchr2.sql]

| Phase | Comm. | Int Stat grp Center | Study | NCIPROTO | Ca Cntrl Temp Study Close |
|-------|--------|------------------------|--|-------------|---------------------------------|
| CC | PREV | N | S00002 SELECT Centralized Follow-up | | Y |
| | SXQOL | N | S1013 Validation Study of FACT-EGFRI | | Y |
| | | Y SWOG | S0702 Zoledronic Acid ONJ Registry | S0702 | Y |
| OTHER | PREV | N | S0000B SELECT Eye Endpoints (SEE) | | Y |
| | | N | S0000D Adenoma Colorectal Polyps (ACP) | | Y |
| I | ERLYTX | N | S0711 Liver dysfunction PK, Dasatinib | | N Y |
| I-II | LUNG | N | S0905 Mesothem, cediranib+chemo, PhI/II | | N |
| | LYMPH | N | S0806 NHL, Adv, R-CHOP + SAHA | | N |
| II | BREAST | Y SWOG | S0800 Brst, Neoadj nabPAC+/-Bev->AC+G | S0800 | N |
| | | Y ACOSOG | Z1071 Node+, chemo + LN dissect | Z1071 | |
| | | Y CALGB | C40603 Carb/Bev+Neoadj Pac, then AC/EC | CALGB-40603 | |
| | | Y ECOG | E3108 CYP2D6 Activity&SingleAgTamox | E3108 | |
| | GI | N | S0713 Rect, Stg2-3, Ox/Cape/Cet+RT->SRG | | N |
| | | N | S1005 Gastric/GEJ, Adv, MK-2206 | | N |
| | | Y SWOG | S0809 EHCC, Adj, Cape+Gem=>Cape+RT | S0809 | N |
| | GU | N | S0925 Andro Dep w/IMC vs. Andro Dep | | N |
| | | N | S1014 Pros, Mets, Abi Acetate | | N |
| | LEUK | N | S0703 AML, age 60+, Azacitidine G.O. | | N |
| | | N | S0910 Rel ph-, B-ALL, Epratuzumab+Cy+Clo | | N |
| | | N | S0919 Rel AML: Pravastatin+Ida+Ara-C | | N |
| | | Y SWOG | S0535 APL, High Risk, ATRA/arsenic/GO | S0535 | N |
| | | Y SWOG | S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT | S0805 | N |
| | | Y CALGB | C10403 ALL <40 yrs-Ped, Chemo. Regimen | CALGB-10403 | N |
| | | Y CALGB | C10404 CLL, Flu/Rituxan combinations | CALGB-10404 | N |
| | | Y ECOG | E1908 Tx of PCL Leuk w/Alemtuz, Ritux | E1908 | |
| | LUNG | N | S0709 NSCLC, Adv, PRO+, OSI-774+-Chemo | | N |
| | | N | S0720 NSCLC, STG I, ERCC1/RRM1 TO ADJ TX | | N Y |

Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center

[comchr2.sql]

| Phase | Comm. | Int Stat grp Center | Study | NCIPROTO | Ca Cntrl Temp Study Close |
|-------|--------|------------------------|---|-------------|---------------------------------|
| II | LUNG | N | S0802 ESCLC,Topotecan+/-AVE0005,PhII | | N |
| | Lymph | Y | SWOG S0816 HD, Adv, PET-Adapted Therapy | S0816 | N |
| | | Y | SWOG S1001 DLBCL, I-II, PET-Adapted Therapy | S1001 | N |
| | | Y | SWOG S1106 NHL, Adv, R-HCVAD/R-Benda+PBSCT | S1106 | N |
| | | Y | SWOG S1108 NHL, Relapsed PTCL, MLN8237 | S1108 | N |
| | | Y | CALGB C50604 Resp-Adapt Chemo Pos Emiss Tomo | CALGB-50604 | |
| | MELAN | Y | ECOG E2607 Dasatinib in KIT+ pts w/Melanoma | E2607 | |
| | MMYEL | N | S0833 Frontline MM, Total Therapy III | | N |
| | PREV | N | S0812 Breast, Prev, Vit D vs Placebo | | Y |
| III | BREAST | Y | SWOG S0500 Brst,Adv,CTC,mntain v chnge tx | S0500 | N |
| | | Y | SWOG S1007 Breast,Adj,N1,Endocrine+/-Chemo | S1007 | Y |
| | | Y | CALGB C40101 Breast, Adj, Node neg, AC vs T | C40101 | |
| | | Y | CALGB C40302 Endocrine +/- Inhibition | CALGB-40302 | |
| | | Y | CALGB C40503 EndocrineTxCombo w/AntiVEGF Tx | CALGB-40503 | |
| | | Y | CALGB C40601 NeoAdj, Her-2+, Pac+Trast or Lap | CALGB-40601 | |
| | | Y | CALGB C70301 QOLEmployInformCareCost Analysis | CALGB-70301 | |
| | | Y | ECOG E1105 Adv, Trastuzumab +/- Bev | E1105 | |
| | | Y | ECOG E2108 Early Local Tx for Int Prim Tum | E2108 | |
| | | Y | ECOG PACCT-1 Assess of Ca Clinical Tests | PACCT-1 | |
| | | Y | IBCSG IBC24-02 Ovar Ftn suppress/premeno | IBCSG-24-02 | |
| | | Y | NCCTG N0434 JMA27 Companion Study | N0434MA27D | |
| | | Y | NCCTG N063D ALTTO | N063D | |
| | | Y | NCCTG N0733 Her2+, Cap + Lap +/- IMC-A12 | N0733 | |
| | | Y | NCIC JMA20 Breast, Early, Regional RT | NCICMA20 | |
| | | Y | NCIC JMA27B 5yr Adj Anast vs Exemestrane | NCIC-MA.27B | |
| | | Y | NCIC MA32 Metformn vs Placebo | NCIC-MA.32 | Y |
| | | Y | NSABP B39 Stg 0-2, whole vs partial RT | NSABP-B-39 | |
| | | Y | NSABP B47 Chemo vs Chemo + Trastuzumab | NSABP-B-47 | |
| | GI | Y | SWOG S0518 CARCINOID,ADV,OCTREO/ALPHA/BEV | S0518 | N |
| | | Y | CALGB C80405 GI,Met,FOLFOX/FIRI,Bev,Cetux | C80405 | |
| | | Y | CALGB C80702 Adj FOLFOX+Celecoxib or Placebo | CALGB-80702 | |
| | | Y | CALGB C80802 Soraf+Doxorubicin vs Sorafenib | CALGB-80802 | |
| | | Y | ECOG E1208 Chemo Soraf. in Unresect HCC | E1208 | |

Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center

[comchr2.sql]

| Phase | Comm. | Int Stat grp Center | Study | NCIPROTO | Ca Cntrl Temp Study Close | |
|-------|-------|--------------------------------------|--|---|---------------------------------|---|
| III | GI | Y | RTOG | R0848 Panc, Adj, Erlotinib v ChemoRT | RTOG-0848 | Y |
| | | Y | RTOG | R1010 Trastuz + Tri Tx of HER2-Overex | RTOG-1010 | |
| | GU | N | | S0337 Blad, Instill Gem vs Saline | | N |
| | | Y | SWOG | S0931 EVEREST | S0931 | N |
| | | Y | SWOG | S1011 Blad, Standard vs Extended LND | S1011 | N |
| | | Y | CALGB | C70807 MEAL Study | CALGB-70807 | |
| | | Y | CALGB | C90202 Pros,Bone mets,Zoledronic acid | CALGB-90202 | |
| | | Y | CALGB | C90203 Pros, Surgery +/- Neoadj Chemo | CALGB-90203 | |
| | | Y | CALGB | C90601 Trans cell, blind bev vs placebo | CALGB-90601 | |
| | | Y | ECOG | E2804 BeST Trial | E2804 | |
| | | Y | ECOG | E2805 Renal, Adj Sunitib v Sorafinib | E2805 | |
| | | Y | ECOG | E3805 CHAARTED | E3805 | |
| | | Y | MDACC | MDA3410 Consolidation chemo | MDA3410 | |
| | | Y | NCIC | PR11 Pros, Local, Watch vs Active Tx | NCIC-PR.11 | N |
| | | Y | RTOG | R0415 Hypofrac v Conv 3D-CRG/IMRT | RTOG-0415 | |
| Y | RTOG | R0521 AS+RT vs AS+RT+Chemo | RTOG-0521 | | | |
| Y | RTOG | R0524 Pac + Trastuzumab vs Pac alone | RTOG-0524 | | | |
| LEUK | Y | ECOG | E2905 MDS, Len vs Len + Epo | E2905 | | |
| LUNG | Y | SWOG | S0819 NSCLC, ADV, CHEMO/BEV +/-CET | S0819 | N | |
| | Y | CALGB | C140503 NSCL, Lobect v Sublobar resect | CALGB-140503 | | |
| | Y | CALGB | C30610 SCLC, Thoracic RT | CALGB-30610 | Y | |
| | Y | CALGB | C30801 Selective COX-2 Inhibition | CALGB-30801 | | |
| | Y | ECOG | E1505 Stg IB-IIIA chemo +/- Bev | E1505 | | |
| | Y | NCCTG | N107C SRS vs WBRT on Resected Met Dz | N107C | | |
| LYMPH | Y | BMT-CT | CTN0701 Relapsed follic, allo transplant | BMT-CTN 0701 | | |
| | N | | | | | |
| | Y | CALGB | C50303 R-CHOP v EPOCH-R | CALGB-50303 | | |
| MELAN | Y | ECOG | E1609 Adj Ipil AntiCTLA4 vs Interferon | E1609 | | |
| MMYEL | Y | SWOG | S0777 MM, Len Dex +/- Bortezomib | S0777 | N | |
| | Y | BMT-CT | CTN0702 Single v Tandem Autol transplant | BMT-CTN 0702 | | |
| | N | | | | | |

Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center

[comchr2.sql]

| Phase | Comm. | Int Stat grp Center | Study | NCIPROTO | Ca Cntrl Temp Study Close |
|-------|-------|------------------------|-------|--|---------------------------------|
| ----- | ----- | ----- | ----- | ----- | ----- |
| III | MMYEL | Y | ECOG | E3A06 Lenalidomide vs Observation | E3A06 |
| | | Y | ECOG | E4A08 MDex vs BMDex in untx pts w/AL | E4A08 |
| | SXQOL | N | | S0927 Omega-3-Fatty Acid AI Joint Pain | Y |

Southwest Oncology Group
Phase III SWOG Coordinated Open Studies
sorted by Study Id

[comchr3.sql]

| Protocol Number | Study | Accrual Goal | Open Stat/Date | Months Open | Accrual as of 01Jan02 | Current Accrual | Proj. Annual Accr. Rate | Expected Closure | Proj. Study Duration (Years) |
|-----------------|--|--------------|----------------|-------------|-----------------------|-----------------|-------------------------|------------------|------------------------------|
| S0337 | Blad, Instill Gem vs Saline (GU) | 408 | Y-07/15/07 | 54 | 312 | 312 | 170 | Aug-2012 | 5.1 |
| S0500 S0500 | Brst,Adv,CTC,mntain v chnge tx (BREAST) | 500 | Y-10/01/06 | 64 | 604 | 604 | 128 | May-2011 | 4.6 |
| S0518 S0518 | CARCINOID,ADV,OCTREO/ALPHA/BEV (GI) | 424 | Y-12/01/07 | 50 | 375 | 375 | 84 | Aug-2012 | 4.7 |
| S0777 S0777 | MM, Len Dex +/- Bortezomib (MMYEL) | 484 | Y-04/01/08 | 46 | 525 | 525 | 188 | Dec-2011 | 3.7 |
| S0819 S0819 | NSCLC, ADV, CHEMO/BEV +/-CET (LUNG) | 1700 | Y-07/15/09 | 30 | 643 | 643 | 320 | May-2015 | 5.8 |
| S0927 | Omega-3-Fatty Acid AI Joint Pain (SXQOL) | 246 | Y-02/01/12 | 0 | 0 | 0 | | | |
| S0931 S0931 | EVEREST (GU) | 1218 | Y-04/01/11 | 10 | 104 | 104 | 194 | Oct-2017 | 6.5 |
| S1007 S1007 | Breast,Adj,N1,Endocrine+/-Chemo (BREAST) | 4000 | Y-01/15/11 | 12 | 252 | 252 | 426 | Nov-2020 | 9.8 |
| S1011 S1011 | Blad, Standard vs Extended LND (GU) | 620 | Y-08/01/11 | 6 | 11 | 11 | 22 | > 15 Yrs | > 15 Yrs |

Accrual goals assume studies are not terminated early as a result of interim analysis.
 Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
 Accrual rate is projected from accrual in the previous six months for studies open at least three months.
 Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.